Insider Buying: Braveheart Bio (NASDAQ:BRVE) Insider Buys $19,998.00 in Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) insider Michele Anderson purchased 1,111 shares of the business’s stock in a transaction on Friday, August 7th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $19,998.00. Following the completion of the transaction, the insider directly owned 332,161 shares in the company, valued at approximately $5,978,898. This represents a 0.34% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Braveheart Bio Stock Performance

Shares of Braveheart Bio stock traded up $0.20 during trading hours on Friday, reaching $30.00. 566,417 shares of the company’s stock were exchanged. Braveheart Bio, Inc. has a fifty-two week low of $28.47 and a fifty-two week high of $32.00.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.